Recherche
Signalisation de l'Invasion tumorale : P. Coopman

Publications

Quesada S, Solassol J, Ray-Coquard I, Fabbro M [Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey]. Bull Cancer. 2023;110(4):371-381. doi:10.1016/j.bulcan.2023.02.004

Mailliez A, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero J-M, Petit T, Mouret-Reynier M, Eymard J-C, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Simon G, Jacot W, Delaloge S Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2023;152(5):921-931. doi:10.1002/ijc.34304

Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton N, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard M, Conde E, Copin M, Côté J, D'Haene N, Dai H, de Leval L, Delongova P, Den?i?-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin J, Mertz K, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti M, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin J, Salmon I, Prince S, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Je?ek S, Solassol J, Steinestel K, Stoj?i? J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl S, Stenzinger A, Ilié M Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open. 2023;8(5):101628. doi:10.1016/j.esmoop.2023.101628

Aptecar L, Puech C, Lopez-Crapez E, Peter M, Coopman P, D'Hondt V, Freiss G PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells. Int J Mol Sci. 2023;24(20):15413. doi:10.3390/ijms242015413

Fabbro M, Jacot W, Jarlier M, Guiu S, D'Hondt V, Champoiral P, Janiszewski C, Nicklès I Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study. Cancer Rep (Hoboken). 2023;6(1):e1732. doi:10.1002/cnr2.1732

Safieddine A, Coleno E, Lionneton F, Traboulsi A-M, Salloum S, Lecellier C-H, Gostan T, Georget V, Hassen-Khodja C, Imbert A, Mueller F, Walter T, Peter M, Bertrand E HT-smFISH: a cost-effective and flexible workflow for high-throughput single-molecule RNA imaging. Nat Protoc. 2023;18(1):157-187. doi:10.1038/s41596-022-00750-2

Vendrell J, Ban I, Solassol I, Audran P, Cabello-Aguilar S, Topart D, Lindet-Bourgeois C, Colombo P-E, Legouffe E, D'Hondt V, Fabbro M, Solassol J Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. Int J Mol Sci. 2023;24(18):14181. doi:10.3390/ijms241814181

Kurtz J-E, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier M-A, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz J-P, Largillier R, Heudel P-E, Heitz F Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023;41(30):4768-4778. doi:10.1200/JCO.23.00529

Dahmani C, Corre E, Dandou S, Mangé A, Radulescu O, Coopman P, Cuq P, Larive R [Resistance to BRAF inhibitors: A lesson from clinical observations]. Med Sci (Paris). 2022;38(6-7):570-578. doi:10.1051/medsci/2022083

Thomas Q, Quesada S, D'Hondt V, Belaroussi I, Laas E, Classe J-M, Fabbro M, Colombo P-E [Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?]. Bull Cancer. 2022;109(2):197-215. doi:10.1016/j.bulcan.2021.11.013

Falandry C, Pommeret F, Gladieff L, Tinquaut F, Lorusso D, Mouret-Reynier M-A, D'Hondt V, Mollon-Grange D, Floquet A, Abadie-Lacourtoisie S, Brachet P-E, Stefani L, Rousseau F, Frenel J-S, Del Piano F, Komulainen M, Warkus T, Pujade-Lauraine E, Freyer G Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. Lancet Healthy Longev. 2022;3(3):e176-e185. doi:10.1016/S2666-7568(22)00002-2

Quesada S, Fabbro M, Solassol J Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. Cancers (Basel). 2022;14(5):1132. doi:10.3390/cancers14051132

Quesada S, Fabbro M, Solassol J Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. Cancers (Basel). 2022;14(4):1098. doi:10.3390/cancers14041098

Bidard F-C, Hardy-Bessard A-C, Dalenc F, Bachelot T, Pierga J-Y, Sabatier R, Dubot C, Frenel J-S, Ferrero J, Ladoire S, Levy C, Mouret-Reynier M-A, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza J, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon J-L, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Delaloge S Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367-1377. doi:10.1016/S1470-2045(22)00555-1

Delaloge S, Dureau S, D'Hondt V, Desmoulins I, Heudel P-E, Duhoux F, Levy C, Lerebours F, Mouret-Reynier M, Dalenc F, Frenel J-S, Jouannaud C, Venat-Bouvet L, Nguyen S, Callens C, Gentien D, Rapinat A, Manduzio H, Vincent-Salomon A, Lemonnier J, Cottu P Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer. 2022;166. doi:10.1016/j.ejca.2022.01.014

Bobrie A, Jarlier M, Moussion A, Jacot W Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures. Support Care Cancer. 2022;30(4):3633-3641. doi:10.1007/s00520-022-06810-3

Marce M, Delaloge S, Hardy-Bessard A-C, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon J-L, André F, Arnould L, Clatot F, Lemonnier J, Marques S Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 2022;12(3):e055821. doi:10.1136/bmjopen-2021-055821

Coopman P Protein Phosphorylation in Cancer: Unraveling the Signaling Pathways. Biomolecules. 2022;12(8):1036. doi:10.3390/biom12081036

Soudier P, Zúñiga A, Duigou T, Voyvodic P, Bazi-Kabbaj K, Kushwaha M, Vendrell J, Bonnet J, Faulon J-L PeroxiHUB: A Modular Cell-Free Biosensing Platform Using H2O2 as Signal Integrator. ACS Synth Biol. 2022;11(8):2578-2588. doi:10.1021/acssynbio.2c00138

Cabello-Aguilar S, Vendrell J, Van Goethem C, Brousse M, Gozé C, Frantz L, Solassol J ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets. Mol Ther Nucleic Acids. 2022;30. doi:10.1016/j.omtn.2022.09.009

Vendrell J, Henry S, Cabello-Aguilar S, Heckendorn E, Godreuil S, Solassol J Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota. Int J Mol Sci. 2022;23(3):1336. doi:10.3390/ijms23031336

de Calbiac O, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier M-A, Emile G, Jouannaud C, Patsouris A, Leheurteur M, Petit T, Cottu P, Ferrero J-M, D'Hondt V, Desmoulins I, Mourato-Ribeiro J, Martin A-L, Frenel J-S Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France. JAMA Netw Open. 2022;5(9):e2231170. doi:10.1001/jamanetworkopen.2022.31170

Thomas Q, Colard-Thomas J, Delansay D, Leenhardt F, Vendrell J, Quantin X Case report: Liquid biopsy, the sooner the better?. Front Oncol. 2022;12. doi:10.3389/fonc.2022.1089108

Pichon X, Moissoglu K, Coleno E, Wang T, Imbert A, Robert M-C, Peter M, Chouaib R, Walter T, Mueller F, Zibara K, Bertrand E, Mili S The kinesin KIF1C transports APC-dependent mRNAs to cell protrusions. RNA. 2021;27(12):1528-1544. doi:10.1261/rna.078576.120

Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Pérol D, Jaffré A, Goncalves A, Lebitasy M-P, D'Hondt V, Dalenc F, Ferrero J-M, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard J-C, Breton M, Chevrot M, Thureau S, Petit T, Simon G Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol. 2021;13. doi:10.1177/1758835920987657



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés